Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
1,001 - 10,000 - Monthly Reach
Unique listeners across all episodes (30 days)
5,001 - 25,000 - Active Followers
Loyal subscribers who consistently listen
501 - 5,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Sickle Cell Disease: New Wave of Gene Therapies
Oct 1, 2025
39m 21s
Roivant: Reinventing the Paradigm of Conventional Drug Development
Jan 5, 2024
51m 27s
Public Relations and Scientific Communications for Biotechnology with Ignacio Guerrero-Ros
Dec 18, 2023
44m 24s
What You Should Know About the Biotech Job Market in 2023 with Carina Clingman
Nov 1, 2023
56m 31s
Antibody-Drug Conjugates: Targeting Cancer Where it is Vulnerable with David Dornan of Elevation Oncology
Oct 9, 2023
28m 53s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 10/1/25 |  Sickle Cell Disease: New Wave of Gene Therapies | Sickle cell disease was once considered an incurable disease, until recently. A wide variety of gene therapies have now become available, allowing patients with sickle cell disease to now have futures once thought unimaginable. In this podcast episode, we talk through these treatments and get expert advice on what these treatments mean for our future. | 39m 21s | ||||||
| 1/5/24 | Roivant: Reinventing the Paradigm of Conventional Drug Development | Roivant Pharma is reinventing the discovery, development, and commercialization of new medicines. Mayukh Sukhatme, M.D. was recently appointed to Roivant's board of directors and has served as Roivant’s President and Chief Investment Officer since January 2021. He is responsible for identifying, performing diligence on, devising development strategies for, and transacting on new therapeutic programs for the company. He also informs Roivant’s view of its existing biopharmaceutical subsidiary c... | 51m 27s | ||||||
| 12/18/23 | Public Relations and Scientific Communications for Biotechnology with Ignacio Guerrero-Ros | Dr. Ignacio Guerrero-Ros is an immunologist turned scientific communicator and biotech media innovator. Currently, he is an Assistant Vice President at Russo Partners, providing public and investor relations services to clients in the healthcare and technology industries. Originally from Spain, Ignacio earned his PhD in Immunology from Albert Einstein College of Medicine. Ignacio embraces the Hopkins Biotech Podcast's mission of the pursuit of alternative careers for PhD holders. In thi... | 44m 24s | ||||||
| 11/1/23 | What You Should Know About the Biotech Job Market in 2023 with Carina Clingman | Carina Clingman, Ph.D., is the Founder and CEO of Recruitomics Consulting, a niche talent acquisition and talent strategy firm specializing in biotech startups. She recently founded The Collaboratory Career Hub to help biotech job seekers find confidence and success in their job search. If you're exploring careers in biotech, join the free Collaboratory Slack Community to work directly with Carina and her team. In this episode, we discuss the state of the biotech job market and offer ad... | 56m 31s | ||||||
| 10/9/23 | Antibody-Drug Conjugates: Targeting Cancer Where it is Vulnerable with David Dornan of Elevation Oncology | About this episode: David Dornan is the Chief Scientific Officer of Elevation Oncology, a clinical-stage biotech company developing targeted cancer therapeutics, with a focus on antibody drug conjugates. David brings to Elevation over two decades of industry and academic oncology drug discovery and development experience. His research spans multiple therapeutic modalities targeting cancer susceptibilities and modulating the immune system to translate into meaningful therapeutic interventions ... | 28m 53s | ||||||
| 8/14/23 | Boston Biotech Series: Standing out in the Competitive Recruiting Process for Early Stage Biotech | Emily Gransky is the Vice President of Recruiting at RA Ventures (RAVen). RAVen is the early-stage venture arm of the multi-stage investment firm RA Capital. In this role, Emily works closely with senior leaders, venture partners, and managing directors within the Venture Team at RA Capital and within RAVen. Her primary responsibility is leading and executing full-cycle recruiting across all newcos and portfolio companies. Prior to RAVen, Emily worked as Director, Talent Acquisition, at Gener... | 29m 23s | ||||||
| 7/17/23 | Boston Biotech Series: Building a Drug Development Platform on New Biology with Isaac Klein of Dewpoint Therapeutics | Dr. Isaac Klein is the Chief Scientific Officer at Dewpoint Therapeutics. Dewpoint Therapeutics is leveraging condensate biology to impact a wide range of therapeutic targets across diverse disease areas. Armed with significant funding from venture capital and several big pharma partnerships, Dewpoint is poised to lead the generation of medicines targeting biomolecular condensates. Prior to joining Dewpoint, Isaac was on the faculty at the Dana Farber Cancer Institute and Harvard Medical Scho... | 38m 20s | ||||||
| 4/17/23 | Boston Biotech Series: Facilitating Start-up Company Formation with Adam Jenkins of Biolabs | Dr. Adam Jenkins is the Regional Site Director for the Massachusetts sites of Biolabs. BioLabs is an international, membership-based network of shared lab and office facilities located in key biotech innovation clusters. Since 2009, over 230 companies have launched from Biolabs facilities, and those member companies have collectively raised more than 1 billion dollars in private financing. With a growing number of sites across the globe, Biolabs is enabling company formation and promoting the... | 36m 26s | ||||||
| 3/20/23 | JPM Highlights: What’s Next in ImmunoOncology | In this episode, we talk with our panel about updates their company gave at the recent JP Morgan Healthcare Conference that took place earlier this year. This once-yearly conference is the epicenter for biotech deal-making and groundbreaking data releases. Dr. Robert Ross is the Chief Executive Officer of Surface Oncology. Surface Oncology’s mission is to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Before becoming... | 59m 00s | ||||||
| 2/27/23 | Lineage Cell Therapeutics: Building an Allogeneic Cell Transplant Therapy Platform | Brian Culley is the CEO of Lineage Cell Therapeutics, a clinical-stage biotech company whose mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions. Lineage currently has several programs undergoing clinical and preclinical investigation for indications in ophthalmology, neurology, and oncology. Prior to joining Lineage in 2018, Brian held a number of senior leadership and executive roles at various biotech compani... | 28m 41s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 2/15/23 | JPM Highlights: Overcoming Complications in Rare Disease Drug Development | In this episode, we talk with our panel about updates their company gave at the recent JP Morgan Healthcare Conference that took place earlier this year. This once-yearly conference is the epicenter for biotech deal-making and groundbreaking data releases. Alejandro Dorenbaum is the Chief Medical Officer of Reneo Pharmaceuticals, a clinical-stage company developing drugs for rare mitochondrial disorders. Their lead clinical candidate REN-001 is currently being investigated in the treatm... | 46m 34s | ||||||
| 1/17/23 | Adrian Rubstein: translating science to business in the Latin American biotech ecosystem | Adrian is an advisor for several biotech companies in Argentina. Before joining CITES, a venture builder from Argentina, he worked as an advisor for RedCrow VC in San Francisco, and has more than 10 years working in the pharmaceutical industry in companies like Novartis and Merck KGaA. In this episode, we discuss his path from academia to big pharma companies and how he made it to the world of Venture Capital and Venture Building. He also shared his thoughts about the role of big pharma... | 53m 45s | ||||||
| 1/9/23 | Cyclacel Pharmaceuticals: Interventions for Cell Cycle Abnormalities in Cancer | Cyclacel Pharmaceuticals is a clinical-stage, biopharmaceutical company, developing innovative cancer medicines based on cell cycle, transcriptional regulation, and mitosis biology with a focus on oncology and hematology indications. Their lead drug candidate, fadraciclib is a dual CDK2/9 inhibitor currently undergoing investigation of dose escalation in a Phase 1/2 trial. Spiro Rombotis is the founding CEO of Cyclacel. Prior to joining Cyclacel, Spiro served in a number of management positio... | 38m 56s | ||||||
| 12/5/22 | Melatech: Unlocking Melanin’s Biotech Potential for the Benefit of Society in Earth and Space | Radamés Cordero is the CEO of Melatech and an associate scientist and junior faculty in the department of Molecular Microbiology and Immunology at Johns Hopkins Bloomberg School of Public Health where he studies the biology of fungal melanin. As a spin-off of his research, Melatech is a biotech company dedicated to the production of melanin at industrial scales and the research and development of melanin-based technologies for a variety of commercial applications like shielding and harvesting... | 47m 11s | ||||||
| 11/21/22 | Ratio Therapeutics: Math Meets Medicine in the Design of Radiotherapies | Ratio Therapeutics is a Boston-based pharmaceutical company with the mission to accelerate the development of best-in-class targeted radiotherapeutics for the treatment of cancers. By employing a suite of innovative technologies the company is developing innovative and proprietary Pharmacokinetics (PK) Modulation technology for the construction of improved therapeutic agents and transforming oncology treatment paradigms. Dr. Jack Hoppin is the co-founder, Chairman, and Chief Executive O... | 43m 27s | ||||||
| 11/14/22 | Anupam Chakravarty: Building Community in the Graduate Education Landscape | Dr. Anupam Chakravarty is a researcher whose research interests have straddled the disciplines of biochemistry and genomics with a keen focus on the biology of cancer. Currently, he is a senior scientist developing liquid biopsy assays and products in the precision oncology space at Guardant Health. Prior to joining Guardant Health, he ran his own lab as an Assistant Professor at the University of Michigan Ann Arbor. He obtained his Ph.D. from Memorial Sloan Kettering in New York City and was... | 40m 24s | ||||||
| 10/31/22 | Tony Russo: A Multi-Decade View of the Biotechnology Industry | Dr. Tony Russo Ph.D. is the Chairman, CEO, and founder of Russo Partners, a leading public and investor relations firm. He has been a member of the healthcare and technology PR and IR community for more than three decades. As a founder of Noonan/Russo in 1988, he and his colleagues have helped build signature healthcare brands worldwide. A frequent speaker at industry conferences, Tony has published articles and chapters in numerous scientific magazines, medical journals and books. He holds a... | 54m 42s | ||||||
| 10/3/22 | Robert Hollingsworth: The Future of iPSC-based Cell Therapy Technology | Dr. Robert Hollingsworth is the current Chief Scientific Officer of Shoreline Biosciences, a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs)- utilizing its proprietary platforms. Dr. Hollingsworth joins Shoreline from Pfizer, where he served as Chief Scientific Officer and Vice President of Cancer Vaccines and Immunotherapeutics. Prior to Pfizer, he was Senior Director of Oncology Research at MedImmune where he led ... | 45m 34s | ||||||
| 9/5/22 | Shelley Ackerman: Immunotherapeutics Development in Graduate School | Dr. Shelley Ackerman is an Associate Director & Program Team Lead at Bolt Biotherapeutics. Bolt is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems. Bolt Biotherapeutics’ proprietary Boltbody™ Immune-stimulating Antibody Conjugates (ISACs) are designed to target tumor cells for elimination by the immune system. BDC-1001 is a HER2-targeting... | 32m 07s | ||||||
| 8/22/22 |  James Coates: Company Growth Through Strategic Advising | Dr. James Coates is currently the Principal for Health & Human Performance at Decisive Point, an East coast venture capital firm that invests in and supports startups with deep tech and government use cases. James holds a Ph.D. in Cancer Drug Discovery and MSc in Radiation Biology and Oncology, both from the University of Oxford, and he conducted technical diligence for Bain Capital Life Sciences prior to joining Decisive Point. In this episode, we discuss his career path and transi... | 24m 21s | ||||||
| 8/8/22 | Philip Kantoff: Next Generation Radiopharmaceutical Drug Development | Dr. Phil Kantoff is the CEO and Co-Founder of Convergent Therapeutics, a clinical-stage pharmaceutical company focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine. Prior to founding the company, Dr. Kantoff spent six years as Chairman of the Department of Medicine at Memoria... | 37m 51s | ||||||
| 7/25/22 | Steve Doberstein: Scaling Technologies from Idea to Clinical Development | Dr. Steve Doberstein has had a long career leading Research groups at a number of biotech companies, like “XOMA”- a monoclonal antibody discovery and development company, “Five Prime Therapeutics”- a protein and antibody discovery and development company, “Xencor”- a leader in protein engineering and “Exelixis”-a genomics-based drug discovery company. Today is the founder and CEO of Kahiliholo Consulting (based in San Francisco), that supports biotech enterprises and early-stage founders. Pri... | 57m 47s | ||||||
| 7/11/22 | Daniel Elgort: Data Driven Insights into the Drug Development Pipeline | Dr. Daniel Elgort currently serves as the Chief Data and Analytics Officer for M2GEN, a bioinformatics company focused on the acceleration of oncology research discoveries through superior data and analytics services. The company was formed as a spin-off of the Moffitt Cancer Center in Tampa, Florida, serving as the technological hub for an alliance of 18 NCI-designated cancer centers across the country called the ORIEN network. Prior to M2GEN, Dan was Chief Scientific Officer at Covera... | 48m 22s | ||||||
| 6/30/22 | Hong Tang: Targeting the Common Side Effects of Cancer Therapies | Hong Tang is the co-founder and Chief Medical Officer of OnQuality Pharmaceuticals, a targeted cancer supportive care (TCSC) pharmaceutical company dedicated to the development of treatments to address specific side effects of cancer therapies- to improve the quality of life and outcomes for patients fighting cancer. Prior to founding OnQuality, she worked as a Physician-Scientist in numerous medical affairs and leadership roles at the NIH, Bristol-Myers Squibb, Astellas Pharma, Dendreon, and... | 26m 14s | ||||||
| 6/21/22 | Apprentice.io: The Future of Digitization in Pharmaceutical Production | Laura Jacoby is currently an Application Specialist at Apprentice.io, an innovative tech company that offers cloud-based solutions that impact pharmaceutical production at every stage of development. Their goal is to introduce digitization of records in an industry that until recently has operated mainly in a paper and pen world. Laura has a career trajectory deeply rooted in pharmaceutical process development and manufacturing sciences working both at the bench and in her capacity as an acco... | 32m 10s | ||||||
Showing 25 of 85
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
2 placements across 2 markets.
Chart Positions
2 placements across 2 markets.